5 Things You Need to Know From AbbVie's Q2 Earnings Results
AbbVie (NYSE: ABBV) needed some good news: Its announcement late last month of a plan to acquire Allergan went over like a lead balloon on Wall Street, and its stock price is down 25% so far this year. Investors continue to worry about the slumping sales of the big pharma company's top-selling drug Humira.
However, the drugmaker gave shareholders a reason to smile when it reported its second-quarter results before the market opened Friday -- because they were better than most analysts expected. Here are five things you need to know about AbbVie's Q2 earnings update.
Image source: Getty Images.
Quelle Fool.com
